BTIG analyst Ryan Zimmerman raised the firm’s price target on Alcon to $91 from $88 and keeps a Buy rating on the shares. MedTech performance in 2Q23 improved sequentially, up 4.6%, and was the best performing Healthcare sub-sector again, but returns were not as robust as the firm expected for the broader group against such a strong fundamental backdrop, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>